ArticlePharmaceutical research2025
Preparation and Characterization of Novel Pan-RAS Inhibitor Loaded Ultraflexible Liposomes for the Topical Prevention or Treatment of Skin Melanoma.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThere are no preventive and few therapeutic options for melanoma, an aggressive skin cancer, especially in situations where N-Ras mutations are present. The new pan-Ras inhibitor ADT-007 has promise for treating melanoma. This study aimed to prepare a topical molecular targeted drug for prevention or treatment of early-stage melanoma using ultraflexible liposomes (UFLs) dispersed in a carbomer gel.
methodsADT-containing UFLs were evaluated for anticancer efficacy and selectivity in vitro using melanoma cell lines and normal keratinocytes. Comparisons were made between UFLs and traditional liposomes (TL) in terms of drug release, encapsulation efficiency, and skin permeation. Permeation tests were conducted using the skin-like Strat-M membrane. Stability of UFLs was assessed at 4°C.
resultsUFLs exhibited enhanced ADT-007 drug release and higher encapsulation efficiency compared to TL. ADT-007 from UFL carbomer gels penetrated more readily through the Strat-M membrane than that from TL or ADT-007 alone. UFLs were incredibly stable in regard to size and encapsulation efficiency, particularly at 4°C. This combination demonstrated low cytotoxicity against human keratinocytes but high toxicity against various human melanoma cancer cells, especially those harboring N-Ras mutations.
conclusionsThis study highlights the use of UFL-based gels as a promising strategy for prevention or targeted melanoma therapy by providing enhanced drug delivery, stability, and cancer cell selectivity.
Indexed as
Identifiers
41298982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.